Lawson and STEMCELL Technologies Announce Partnership for Commercialization of Tools for Parkinson’s Disease Research
Offering Insight Into the Disease Process and Treatment Options
LONDON - Lawson Health Research Institute (Lawson) and STEMCELL Technologies Inc. announced that they have signed a license agreement giving STEMCELL global exclusive rights to commercialize novel tools for Parkinson’s Disease research.
Parkinson’s Disease is the second most common neurodegenerative disorder, after Alzheimer’s disease, affecting about seven to ten million people around the world. It is characterized by progressive neurological impairment that produces tremor, slowness of movement, impaired balance, muscle rigidity, cognitive decline and other medical disturbances. The symptoms are caused by the death of cells in the nervous system, including those that generate dopamine, which is a chemical neurotransmitter that sends signals between nerve cells. Although specific gene mutations have been identified in a minority of patients, there is no known cause in most individuals. There is currently no cure for Parkinson’s Disease. “We are delighted for the opportunity to bring these important products to the research community and we are excited to be the exclusive supplier," said Dr. Allen Eaves, CEO and President of STEMCELL Technologies.
A team led by Dr. Matthew Hebb, a neurosurgeon-researcher at Lawson and Western University’s Department of Clinical Neurological Sciences has been developing innovative strategies to study Parkinson’s Disease. “The partnership with STEMCELL Technologies greatly expands the expertise focused on moving this technology forward and providing critical access to researchers worldwide.” says Dr. Hebb.
As the research institute of London Health Sciences Centre and St. Joseph's Health Care London, and working in partnership with Western University, Lawson Health Research Institute is committed to furthering scientific knowledge to advance health care around the world. Commercialization at Lawson is facilitated by WORLDiscoveries®, a joint venture of Lawson, Western, and Robart’s Research Institute. As the business development arm of London, Ontario’s extensive research network, it is a bridge between local invention and global industry.